 "Dr Reddy's Q2FY26 results: Profit up 14% at ₹1,437.2 cr, revenue jumps 10%")
Hyderabad-based pharma major Dr Reddy Laboratories on Friday reported a consolidated net profit of ₹1,437.2 crore in the second quarter of the financial year 2025-26 (Q2FY26), marking a 14 per cent increase from the ₹1,255.3 crore it posted in the corresponding quarter last fiscal. On a sequential basis, profit remained largely unchanged.
Dr Reddy's Labs' earnings before interest, taxes, depreciation, and amortization (Ebitda) for the quarter stood at ₹2,351.1 crore, up 3 per cent Y-o-Y and sequentially, with an Ebitda margin of 26.7 per cent.
Revenue from operations for the quarter stood at ₹8,805.1 crore, up 9.8 per cent from ₹8,016.2 crore in Q2FY25. Sequentially, it increased 3 per cent from ₹8,545.2 crore.
"Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRT) portfolio, which helped offset the decline in US Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and pursuing business development initiatives," said G V Prasad, co-chairman and managing director of Dr Reddy's Laboratories.
Here's a look at the drug maker's segment wise sales:
North America: ₹3,241 crore, down 13 per cent
Europe: ₹1,376 crore, up 138 per cent
India: ₹1,578 crore, up 13 per cent
Emerging markets: ₹1,655 crore, up 14 per cent
Dr Reddy Laboratories Q2 results highlights
- Revenue from operations: ₹8,805.1 crore
- Net profit: ₹1,437.2 crore
- Earnings per share (EPS): ₹17.26 (basic) and ₹17.25 (diluted)